Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

Zydus receives approval from Health Canada for Liothyronine tablets 5 mcg and 25 mcg

By: IPP Bureau

Last updated : October 07, 2025 3:08 pm



Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ


Zydus Lifesciences Limited has received NOC (Notice of Compliance) from Health Canada for generic Liothyronine tablets 5 mcg and 25 mcg.

Liothyronine tablets, a synthetic form of the thyroid hormone T3 (triiodothyronine), are primarily indicated for treating hypothyroidism.

ZDS - Liothyronine tablets will be manufactured at Zydus' plant in Ahmedabad SEZ. Liothyronine tablets had annual sales of 10.9 mn CAD (Canadian Dollars) in Canada (IQVIA MAT June 2025).

Zydus Lifesciences Limited USFDA Liothyronine

First Published : October 07, 2025 12:00 am